A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults
Key facts
- Who runs it
- argenx
- Where
- Sherman and Tucson, United StatesSee the 2 sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 170 people, planned
- Starts
- 1 Apr 2027
- Expected to end
- 30 Jul 2030
- Type of study
- Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Efgartigimod PH20 (ARGX-113) SC
- Placebo PH20 SC
- Record updated
- 22 September 2026
Who can take part
- Age
- 12 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Is at least 12 years of age
- Meeting at least the criteria for possible AIE according to the Graus criteria
- Part A:; Must not have received prior treatment for AIE with PLEX or Ig (participants may have received glucocorticoids); and must not have received PLEX or Ig for any other medical condition in the last 3 months
- Part B: Either completing Part A, or If directly entering Part B, must have received first-line treatment for AIE (i.e. corticosteroids, PLEX, and/or Ig) and have a CASE score of 3 or higher, or a score of 2 or higher in a single sub-item
Who cannot take part
- Known anti-myelin oligodendrocyte glycoprotein (anti-MOG) antibody positivity
- Recent major surgery (within 3 months of screening) or intention to have major surgery during the study, except for surgeries for AIE-related teratomas and thymomas
- History (within 12 months before screening) of current alcohol, drug (including recreational or prescribed cannabinoids), or medication abuse
- Any medical condition that would interfere with an accurate assessment of clinical symptoms of AIE
- Psychiatric or cognitive impairment unrelated to AIE
Where in United States
- Texas Institute for Neurological DisordersSherman, United StatesContact: Laurie LaurieNot yet recruiting
- Center for NeurosciencesTucson, United StatesContact: Gwendolyn GrabiecNot yet recruiting
About the trial
What the trial wants to find out
The POLARIS study is designed to evaluate how well efgartigimod PH20 SC may work (called "efficacy") and how safe it is for people diagnosed with Autoimmune Encephalitis (AIE). The study consists of 4 parts: in part A participants will receive efgartigimod SC; in part B, participants will be randomized to receive either efgartigimod SC or placebo; in part C, participants who completed part B will receive efgartigimod SC; in part D, participants who completed part C will be observed after their last dose of efgartigimod SC. If AIE symptoms return, efgartigimod SC treatment may be restarted during this time.
Read full original descriptionShow less
The maximum overall study duration for participants is up to 3 years. More information can be found in clinicaltrials.argenx.com/polaris
The 4 groups in the trial
- Part A (Open-Label Lead-in Period): Efgartigimod PH20 SCTreatment being tested
All participants will receive efgartigimod PH20 SC open label for 8 weeks
Treatment: Efgartigimod PH20 (ARGX-113) SC
- Part B (Double-blinded treatment period): Efgartigimod PH20 SCTreatment being tested
Participants will receive efgartigimod PH20 SC for 24 weeks
Treatment: Efgartigimod PH20 (ARGX-113) SC
- Part B (Maintenance double-blinded treatment period): Placebo PH20 SCPlacebo, for comparison
Participants will receive placebo for 24 weeks
Treatment: Placebo PH20 SC
- Part C (Open-Label Extension Period): Efgartigimod PH20 SCTreatment being tested
Participants who complete Part B will receive efgartigimod PH20 SC for 24 weeks
Treatment: Efgartigimod PH20 (ARGX-113) SC
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Global, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult and Adolescent Participants With Autoimmune Encephalitis
- Record updated
- 22 September 2026